【摘要】：目的:探討10 mg/d瑞舒伐他汀和20 mg/d阿托伐他汀治療高脂血癥(HLP)的有效性和經(jīng)濟(jì)性。方法:回顧性收集2015年3月-2016年2月天門(mén)市第一人民醫(yī)院門(mén)診收治的180例確診為HLP的患者資料,根據(jù)治療方案不同分為A、B組,各90例。A組患者給予阿托伐他汀鈣片20 mg,qd;B組患者給予瑞舒伐他汀鈣片10 mg,qd。兩組患者療程均為8周。比較兩組患者治療前后的血脂指標(biāo)水平和治療后的降脂療效、血脂達(dá)標(biāo)率及不良反應(yīng)發(fā)生情況,并運(yùn)用成本-效果分析法進(jìn)行經(jīng)濟(jì)學(xué)評(píng)價(jià)。結(jié)果:治療前,兩組患者的血脂指標(biāo)水平比較,差異均無(wú)統(tǒng)計(jì)學(xué)意義(P0.05)。治療后,兩組患者的總膽固醇和低密度脂蛋白膽固醇水平均明顯低于治療前,且B組水平明顯低于A(yíng)組,差異均有統(tǒng)計(jì)學(xué)意義(P0.05);B組患者的降脂總有效率(97.78%)顯著高于A(yíng)組(86.67%),血脂達(dá)標(biāo)率(66.67%)也顯著高于A(yíng)組(51.11%),差異均有統(tǒng)計(jì)學(xué)意義(P0.05)。兩組患者不良反應(yīng)發(fā)生率比較,差異無(wú)統(tǒng)計(jì)學(xué)意義(P0.05)。A組和B組方案的成本分別為488.32、436.24元,成本-效果比分別為5.63、4.46,增量成本-效果比為-4.69,B組方案更具有成本-效果優(yōu)勢(shì)。敏感度分析支持成本-效果分析結(jié)果。結(jié)論:從短期療效上分析,10 mg/d瑞舒伐他汀方案較20 mg/d阿托伐他汀方案的降脂效果更好,更具有成本-效果優(yōu)勢(shì),且二者安全性相當(dāng)。
[Abstract]:Objective: to investigate the efficacy and economy of 10 mg/d resuvastatin and 20 mg/d Atto vastatin in the treatment of hyperlipidemia (HLP). Methods: 180 patients with HLP were collected retrospectively from March 2015 to February 2016 in the first people's Hospital of Tianmen City. 90 patients in group A were treated with Atto vastatin calcium tablets (20 mg / g QD) and group B were treated with rosuvastatin calcium tablets (10 mg / g QD). The course of treatment was 8 weeks. The level of blood lipid index, the effect of lowering blood lipid, the rate of blood lipid reaching standard and the occurrence of adverse reaction were compared between the two groups before and after treatment, and the economic evaluation was carried out by cost-effect analysis method. Results: before treatment, there was no significant difference in blood lipid levels between the two groups (P0.05). After treatment, the levels of total cholesterol and low density lipoprotein cholesterol in both groups were significantly lower than those before treatment, and the levels in group B were significantly lower than those in group A. The total effective rate (97.78%) of group B was significantly higher than that of group A (86.67%), and the rate of blood lipid reaching standard (66.67%) was significantly higher than that of group A (51.11%), the difference was statistically significant (P0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P0.05). The cost of group A and group B was 488.32436.24 yuan, respectively. The cost-effect ratio was 5.63% 4.46, and the incremental cost-effect ratio was -4.69%. Sensitivity analysis supports cost-effect analysis results. Conclusion: compared with that of 20 mg/d Atto vastatin regimen, rosuvastatin regimen for 10 mg/d is more effective and cost effective, and its safety is similar.
【作者單位】： 天門(mén)市第一人民醫(yī)院藥劑科;武漢大學(xué)人民醫(yī)院心血管內(nèi)科;
【基金】：國(guó)家自然科學(xué)基金資助項(xiàng)目(No.81370365)
【分類(lèi)號(hào)】：R589.2

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 陳金秀;王迪;李國(guó)峰;高恩民;王浩;;2種方案治療高血壓合并高血脂癥成本-效果分析[J];醫(yī)藥論壇雜志;2006年12期

2 何蓮英;;兩種方案治療2型糖尿病的成本-效果分析[J];海峽藥學(xué);2009年06期

3 季興繁;;兩種方案治療2型糖尿病的成本-效果分析[J];海峽藥學(xué);2008年10期

4 謝樹(shù)斌;4種用藥方案治療2型糖尿病的成本-效果分析[J];中國(guó)藥房;2005年12期

5 陳妍;葉君霞;;2型糖尿病3種治療方案的成本-效果分析[J];安徽醫(yī)藥;2008年02期

6 林亮;葛燕平;;我院治療2型糖尿病常見(jiàn)3種方案的成本-效果分析[J];醫(yī)學(xué)信息(上旬刊);2010年09期

7 陳靈;張婉婷;;4種用藥方案治療2型糖尿病的成本-效果分析[J];中國(guó)藥房;2006年10期

8 楊華;吳秀榮;林煥澤;;治療2型糖尿病3種用藥方案的成本-效果分析[J];中國(guó)醫(yī)藥導(dǎo)報(bào);2010年27期

9 侯利強(qiáng);;3種方案治療2型糖尿病的成本-效果分析[J];山西醫(yī)藥雜志(下半月刊);2009年08期

10 賀桂泉;岳剛;陳振瑾;;5種口服用藥方案治療2型糖尿病的成本-效果分析[J];天津藥學(xué);2007年03期

相關(guān)會(huì)議論文 前1條

1 黎小妍;張平;曲彩虹;謝志忠;;阿托伐他汀和辛伐他汀調(diào)脂療效的成本-效果分析[A];2009年中國(guó)藥學(xué)大會(huì)暨第九屆中國(guó)藥師周論文集[C];2009年

，

本文編號(hào)：2129956